CO6791612A2 - Piridinilo- y pirazinilo-metiloxi - arilo derivados útiles como inhibidores de tirosina quinasa del bazo (syk) - Google Patents

Piridinilo- y pirazinilo-metiloxi - arilo derivados útiles como inhibidores de tirosina quinasa del bazo (syk)

Info

Publication number: CO6791612A2
Authority: CO; Colombia
Prior art keywords: methyloxy; syk; pyridinyl; pyrazinyl; tyrosine kinase
Prior art date: 2011-03-11

Application number

CO13197322A

Other languages

English (en)

Inventor

Francis Louis Atkinson

Michael David Barker

John Liddle

David Matthew Wilson

Original Assignee

Glaxo Group Ltd

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2011-03-11

Filing date

2013-08-20

Publication date

2013-11-14

2013-08-20 Application filed by Glaxo Group Ltd filed Critical Glaxo Group Ltd

2013-11-14 Publication of CO6791612A2 publication Critical patent/CO6791612A2/es

Classifications

- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/472—Non-condensed isoquinolines, e.g. papaverine
- A61K31/4725—Non-condensed isoquinolines, e.g. papaverine containing further heterocyclic rings
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0014—Skin, i.e. galenical aspects of topical compositions
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/04—Antipruritics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/04—Drugs for skeletal disorders for non-specific disorders of the connective tissue
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings

Landscapes

Health & Medical Sciences (AREA)
Chemical & Material Sciences (AREA)
Organic Chemistry (AREA)
Veterinary Medicine (AREA)
Pharmacology & Pharmacy (AREA)
Public Health (AREA)
General Health & Medical Sciences (AREA)
Animal Behavior & Ethology (AREA)
Medicinal Chemistry (AREA)
Life Sciences & Earth Sciences (AREA)
General Chemical & Material Sciences (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Chemical Kinetics & Catalysis (AREA)
Engineering & Computer Science (AREA)
Bioinformatics & Cheminformatics (AREA)
Epidemiology (AREA)
Immunology (AREA)
Dermatology (AREA)
Rheumatology (AREA)
Physical Education & Sports Medicine (AREA)
Pulmonology (AREA)
Hematology (AREA)
Pain & Pain Management (AREA)
Transplantation (AREA)
Heart & Thoracic Surgery (AREA)
Biomedical Technology (AREA)
Diabetes (AREA)
Orthopedic Medicine & Surgery (AREA)
Urology & Nephrology (AREA)
Cardiology (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Plural Heterocyclic Compounds (AREA)
Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

CO13197322A 2011-03-11 2013-08-20 Piridinilo- y pirazinilo-metiloxi - arilo derivados útiles como inhibidores de tirosina quinasa del bazo (syk) CO6791612A2 (es)

Applications Claiming Priority (1)

Application Number	Priority Date	Filing Date	Title
GBGB1104153.0A GB201104153D0 (en)	2011-03-11	2011-03-11	Novel compounds

Publications (1)

Publication Number	Publication Date
CO6791612A2 true CO6791612A2 (es)	2013-11-14

Family

ID=43980841

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
CO13197322A CO6791612A2 (es)	2011-03-11	2013-08-20	Piridinilo- y pirazinilo-metiloxi - arilo derivados útiles como inhibidores de tirosina quinasa del bazo (syk)

Country Status (42)

Country	Link
US (4)	US20140005177A1 (es)
EP (2)	EP2937344B1 (es)
JP (1)	JP5902206B2 (es)
KR (1)	KR101564007B1 (es)
CN (1)	CN103502239B (es)
AR (1)	AR085711A1 (es)
AU (1)	AU2012228439C1 (es)
BR (1)	BR112013022784A2 (es)
CA (1)	CA2828518C (es)
CL (1)	CL2013002602A1 (es)
CO (1)	CO6791612A2 (es)
CR (1)	CR20130459A (es)
CY (2)	CY1116569T1 (es)
DK (2)	DK2683709T3 (es)
DO (1)	DOP2013000207A (es)
EA (1)	EA022437B1 (es)
ES (2)	ES2641483T3 (es)
GB (1)	GB201104153D0 (es)
HK (2)	HK1192887A1 (es)
HR (2)	HRP20150752T1 (es)
HU (2)	HUE026541T2 (es)
IL (1)	IL227873A (es)
JO (1)	JO3072B1 (es)
LT (1)	LT2937344T (es)
MA (1)	MA35030B1 (es)
ME (2)	ME02872B (es)
MX (1)	MX339123B (es)
MY (1)	MY169314A (es)
NO (1)	NO2937344T3 (es)
PE (1)	PE20140998A1 (es)
PH (1)	PH12013501854A1 (es)
PL (2)	PL2683709T3 (es)
PT (2)	PT2937344T (es)
RS (2)	RS54120B1 (es)
SG (1)	SG193015A1 (es)
SI (2)	SI2683709T1 (es)
SM (2)	SMT201700538T1 (es)
TW (1)	TWI527806B (es)
UA (1)	UA109807C2 (es)
UY (1)	UY33942A (es)
WO (1)	WO2012123311A1 (es)
ZA (1)	ZA201306554B (es)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
WO2014081616A1 (en) *	2012-11-21	2014-05-30	Merck Sharp & Dohme Corp.	Preparation of precursors for leukotriene antagonists
RU2018106663A (ru) *	2015-07-24	2019-08-26	Глэксо Груп Лимитед	Лечение витилиго
EP3665171A1 (en)	2017-10-19	2020-06-17	Bayer Animal Health GmbH	Use of fused heteroaromatic pyrrolidones for treatment and prevention of diseases in animals
AU2020242287A1 (en)	2019-03-21	2021-09-02	INSERM (Institut National de la Santé et de la Recherche Médicale)	A Dbait molecule in combination with kinase inhibitor for the treatment of cancer
EP3958851B1 (en) *	2019-04-23	2024-08-14	The Cleveland Clinic Foundation	Allosteric activators of the alpha ia-adrenergic receptor
EP4054579A1 (en)	2019-11-08	2022-09-14	Institut National de la Santé et de la Recherche Médicale (INSERM)	Methods for the treatment of cancers that have acquired resistance to kinase inhibitors
WO2021148581A1 (en)	2020-01-22	2021-07-29	Onxeo	Novel dbait molecule and its use
CN113340965B (zh) *	2020-03-03	2022-12-16	北京中医药大学	一种用于检测扑尔敏用途的人工智能生物传感器检测方法

Family Cites Families (102)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
BE887518A (fr)	1980-02-15	1981-08-13	Glaxo Group Ltd	Cartothioates d'androstanes
AU570439B2 (en)	1983-03-28	1988-03-17	Compression Labs, Inc.	A combined intraframe and interframe transform coding system
GB9004781D0 (en)	1990-03-02	1990-04-25	Glaxo Group Ltd	Device
FR2665159B1 (fr)	1990-07-24	1992-11-13	Rhone Poulenc Sante	Nouveaux derives de la pyridine et de la quinoleine, leur preparation et les compositions pharmaceutiques qui les contiennent.
GB9127376D0 (en)	1991-12-24	1992-02-19	Wellcome Found	Amidino derivatives
EP0633776B1 (en)	1992-04-02	2001-05-09	Smithkline Beecham Corporation	Compounds useful for treating allergic and inflammatory diseases
IL108630A0 (en) *	1993-02-18	1994-05-30	Fmc Corp	Insecticidal substituted 2,4-diaminoquinazolines
US5426196A (en)	1993-12-22	1995-06-20	Glaxo Inc.	Synthesis of diaryl methanes
WO1995034534A1 (en)	1994-06-15	1995-12-21	The Wellcome Foundation Limited	Enzyme inhibitors
US6017919A (en)	1996-02-06	2000-01-25	Japan Tobacco Inc.	Compounds and pharmaceutical use thereof
MY117948A (en)	1997-01-13	2004-08-30	Glaxo Group Ltd	Nitride oxide synthase inhibitors.
WO1998050030A1 (en)	1997-05-07	1998-11-12	University Of Pittsburgh	Inhibitors of protein isoprenyl transferases
DE19723722A1 (de)	1997-05-30	1998-12-10	Schering Ag	Nichtsteroidale Gestagene
AU9281298A (en)	1997-10-01	1999-04-23	Kyowa Hakko Kogyo Co. Ltd.	Benzodioxole derivatives
EP1019391A1 (en)	1997-10-02	2000-07-19	Merck & Co. Inc.	Inhibitors of prenyl-protein transferase
EP1054004B1 (en)	1997-12-15	2008-07-16	Astellas Pharma Inc.	Novel pyrimidine-5-carboxamide derivatives
ATE271555T1 (de)	1998-01-14	2004-08-15	Uab Research Foundation	Verfahren zur herstellung und screening von inhibitoren des bakteriellen nad synthetase enzyms, verbindungen daraus und methoden zur behandlung bakterieller und mikrobieller infektionen mit diesen inhibitoren
US6506766B1 (en)	1998-02-13	2003-01-14	Abbott Laboratories	Glucocortiocoid-selective antinflammatory agents
SI1070056T1 (en)	1998-03-14	2004-12-31	Altana Pharma Ag	Phthalazinone pde iii/iv inhibitors
AU4072799A (en)	1998-05-12	1999-12-13	American Home Products Corporation	2,3,5-substituted biphenyls useful in the treatment of insulin resistance and hyperglycemia
GB9811599D0 (en)	1998-05-30	1998-07-29	Glaxo Group Ltd	Nitric oxide synthase inhibitors
CA2362401A1 (en)	1999-02-04	2000-08-10	Paul Fleming	G-protein coupled heptahelical receptor binding compounds and methods of use thereof
WO2000069823A1 (en)	1999-05-12	2000-11-23	Neurosearch A/S	Ion channel modulating agents
EP1175422A2 (en)	1999-05-04	2002-01-30	Ligand Pharmaceuticals Incorporated	Tetracyclic progesterone receptor modulator compounds and methods
EP1194135A2 (en)	1999-06-29	2002-04-10	The UAB Research Foundation	Methods of treating fungal infections with inhibitors of nad synthetase enzyme
ES2165768B1 (es)	1999-07-14	2003-04-01	Almirall Prodesfarma Sa	Nuevos derivados de quinuclidina y composiciones farmaceuticas que los contienen.
CO5180649A1 (es)	1999-09-01	2002-07-30	Abbott Lab	Antagonistas de los receptores de los glucocorticoides para el tratamiento de la diabetes para el tratamiento de la diabetes
OA11558A (en)	1999-12-08	2004-06-03	Advanced Medicine Inc	Beta 2-adrenergic receptor agonists.
JP3831253B2 (ja)	2000-04-04	2006-10-11	塩野義製薬株式会社	高脂溶性化合物を含有する油性組成物
AU2001244610A1 (en)	2000-04-05	2001-10-23	Shionogi And Co., Ltd.	Oil-in-water microemulsions containing tricyclic compounds or preconcentrates thereof
IL154148A0 (en)	2000-08-05	2003-07-31	Glaxo Group Ltd	6.alpha.,9.alpha.-difluoro-17.alpha.-'(2-furanylcarboxyl) oxyl-11.beta.-hydroxy-16.alpha.-methyl-3-oxo-androst-1,4-diene-17-carbothioic acid s-fluoromethyl ester as an anti-inflammatory agent
AR035205A1 (es)	2000-09-29	2004-05-05	Glaxo Group Ltd	Compuestos utiles en el tratamiento de enfermedades inflamatorias, proceso para su preparacion, intermediarios y composiciones farmaceuticas
GB0031179D0 (en)	2000-12-21	2001-01-31	Glaxo Group Ltd	Nitric oxide synthase inhibitors
US6484903B2 (en)	2001-01-09	2002-11-26	Riverwood International Corporation	Carton with an improved dispensing feature in combination with a unique handle
GB0103630D0 (en)	2001-02-14	2001-03-28	Glaxo Group Ltd	Chemical compounds
WO2002070490A1 (en)	2001-03-08	2002-09-12	Glaxo Group Limited	Agonists of beta-adrenoceptors
ES2296923T3 (es)	2001-03-22	2008-05-01	Glaxo Group Limited	Derivados formanilidas como agonistas del adrenorreceptor beta2.
DK1383786T3 (da)	2001-04-30	2009-01-12	Glaxo Group Ltd	Antiinflammatoriske 17-beta-carbothioatesterderivater af androstan med en cyklisk estergruppe i 17alfa-stilling
EP1395604B1 (en)	2001-06-12	2008-06-25	Glaxo Group Limited	Novel anti inflammatory 17.alpha.-heterocyclic-esters of 17.beta.-carbothioate androstane derivatives
JP2005509594A (ja)	2001-07-13	2005-04-14	バーチャルドラッグディヴェロップメント、インコーポレイティッド	Ｎａｄシンテターゼ阻害剤およびその使用
DE60230425D1 (de)	2001-09-14	2009-01-29	Glaxo Group Ltd	Phenethanolamin-derivate zur behandlung von erkrankungen der atemwege
US6653323B2 (en)	2001-11-13	2003-11-25	Theravance, Inc.	Aryl aniline β2 adrenergic receptor agonists
WO2003050174A1 (en)	2001-12-11	2003-06-19	Rhodia Chimie	Catalytic pgm mixture for hydrosilylation
US20030187026A1 (en)	2001-12-13	2003-10-02	Qun Li	Kinase inhibitors
US20030158195A1 (en)	2001-12-21	2003-08-21	Cywin Charles L.	1,6 naphthyridines useful as inhibitors of SYK kinase
ATE346058T1 (de)	2002-01-14	2006-12-15	Boehringer Ingelheim Pharma	Glucocorticoid mimetika, verfahren zu ihrer herstellung, pharmazeutische formulierungen sie enthaltend und verwendungen davon
CA2473886C (en)	2002-01-22	2012-08-21	The Regents Of The University Of California	Non-steroidal ligands for the glucocorticoid receptor, compositions and uses thereof
GB0204719D0 (en)	2002-02-28	2002-04-17	Glaxo Group Ltd	Medicinal compounds
NZ535889A (en)	2002-03-26	2006-03-31	Boehringer Ingelheim Pharma	Glucocorticoid mimetics, methods of making them, pharmaceutical compositions, and uses thereof
EP1490317A1 (en)	2002-03-26	2004-12-29	Boehringer Ingelheim Pharmaceuticals Inc.	Glucocorticoid mimetics, methods of making them, pharmaceutical compositions, and uses thereof
DE10215316C1 (de)	2002-04-02	2003-12-18	Schering Ag	Chinolin- und Isochinolin-Derivate, ein pharmazeutisches Mittel und ihre Verwendung als Entzündungshemmer
ATE496620T1 (de)	2002-04-11	2011-02-15	Merck Sharp & Dohme	1h-benzo(f)indazol-5-yl-derivate als selektive glucocorticoid-rezeptor-modulatoren
WO2003091204A1 (en)	2002-04-25	2003-11-06	Glaxo Group Limited	Phenethanolamine derivatives
US7186864B2 (en)	2002-05-29	2007-03-06	Boehringer Ingelheim Pharmaceuticals, Inc.	Glucocorticoid mimetics, methods of making them, pharmaceutical compositions, and uses thereof
US7074806B2 (en)	2002-06-06	2006-07-11	Boehringer Ingelheim Pharmaceuticals, Inc.	Glucocorticoid mimetics, methods of making them, pharmaceutical compositions, and uses thereof
PT1521733E (pt)	2002-07-08	2014-10-29	Pfizer Prod Inc	Moduladores do recetor de glucocorticoides
PL375442A1 (en)	2002-07-18	2005-11-28	Bristol-Myers Squibb Company	Modulators of the glucocorticoid receptor and method
GB0217225D0 (en)	2002-07-25	2002-09-04	Glaxo Group Ltd	Medicinal compounds
WO2004018429A2 (en)	2002-08-21	2004-03-04	Boehringer Ingelheim Pharmaceuticals, Inc.	Substituted hihydroquinolines as glucocorticoid mimetics, methods of making them, pharmaceutical compositions, and uses thereof
GB0220730D0 (en)	2002-09-06	2002-10-16	Glaxo Group Ltd	Medicinal compounds
GB0230045D0 (en)	2002-12-23	2003-01-29	Glaxo Group Ltd	Compounds
CN100387598C (zh)	2002-09-16	2008-05-14	葛兰素集团有限公司	吡唑并[3,4-b]吡啶化合物及其作为磷酸二酯酶抑制剂的用途
AU2003270783C1 (en)	2002-09-20	2010-05-20	Merck Sharp & Dohme Corp.	Octahydro-2-H-naphtho[1,2-F] indole-4-carboxamide derivatives as selective glucocorticoid receptor modulators
GB0224084D0 (en)	2002-10-16	2002-11-27	Glaxo Group Ltd	Novel compounds
AU2003301433A1 (en)	2002-10-16	2004-05-04	Millennium Pharmaceuticals, Inc.	Spleen tyrosine kinase catalytic domain:crystal structure and binding pockets thereof
DE60315492T2 (de)	2002-10-22	2008-04-24	Glaxo Group Ltd., Greenford	Medizinisch verwendbare arylethanolamin verbindungen
GB0225030D0 (en)	2002-10-28	2002-12-04	Glaxo Group Ltd	Medicinal compounds
SI1556342T1 (sl)	2002-10-28	2008-08-31	Glaxo Group Ltd	Fenetanolaminski derivat za zdravljenje respiratornih bolezni
GB0225540D0 (en)	2002-11-01	2002-12-11	Glaxo Group Ltd	Medicinal compounds
GB0225535D0 (en)	2002-11-01	2002-12-11	Glaxo Group Ltd	Medicinal compounds
ES2401216T3 (es)	2002-12-20	2013-04-17	Glaxo Group Limited	Nuevos derivados de benzazepina
TWI328009B (en)	2003-05-21	2010-08-01	Glaxo Group Ltd	Quinoline derivatives as phosphodiesterase inhibitors
GB0316290D0 (en)	2003-07-11	2003-08-13	Glaxo Group Ltd	Novel compounds
WO2005016862A1 (en) *	2003-08-14	2005-02-24	Asahi Kasei Pharma Corporation	Substituted arylalkanoic acid derivative and use thereof
US8752543B2 (en)	2003-11-03	2014-06-17	Glaxo Group Limited	Fluid dispensing device
JP2005170939A (ja)	2003-11-20	2005-06-30	Takeda Chem Ind Ltd	糖尿病の予防・治療剤
ES2433466T3 (es)	2004-02-27	2013-12-11	Amgen, Inc	Compuestos, composiciones farmacéuticas y métodos para su uso en el tratamiento de trastornos metabólicos
CA2555914A1 (en)	2004-03-08	2005-09-22	Amgen Inc.	Therapeutic modulation of ppar (gamma) activity
WO2006000398A1 (en)	2004-06-28	2006-01-05	Glaxo Group Limited	2,3-benzoxazin derivatives as non-steroidal glucocorticoid receptor modulators
WO2006000401A1 (en)	2004-06-28	2006-01-05	Glaxo Group Limited	Substituted oxazines as glucocorticoid receptor modulators
GB0418045D0 (en)	2004-08-12	2004-09-15	Glaxo Group Ltd	Compounds
WO2006045416A1 (en)	2004-10-19	2006-05-04	F. Hoffmann-La Roche Ag	Quinoline derivatives
EP1841780B1 (en)	2005-01-10	2011-07-27	Glaxo Group Limited	Androstane 17-alpha-carbonate derivatives for use in the treatment of allergic and inflammatory conditions
US20090124588A1 (en)	2005-01-10	2009-05-14	Glaxo Group Limited	Androstane 17-Alpha-Carbonate for Use in the Treatment of Inflammatory and Allergic Conditions
US8968708B2 (en)	2005-02-04	2015-03-03	Senomyx, Inc.	Compounds comprising linked heteroaryl moieties and their use as novel umami flavor modifiers, tastants and taste enhancers for comestible compositions
EP1869003B1 (en)	2005-04-14	2013-05-15	Glaxo Group Limited	Indazoles as glucocorticoid receptor ligands
GB0513297D0 (en)	2005-06-29	2005-08-03	Glaxo Group Ltd	Novel compounds
TW200740805A (en) *	2005-07-15	2007-11-01	Glaxo Group Ltd	Novel compounds
JP2007063225A (ja) *	2005-09-01	2007-03-15	Takeda Chem Ind Ltd	イミダゾピリジン化合物
CA2621949A1 (en)	2005-09-14	2007-03-22	Amgen Inc.	Conformationally constrained 3- (4-hydroxy-phenyl) - substituted-propanoic acids useful for treating metabolic disorders
US20070225285A1 (en)	2005-11-04	2007-09-27	Amira Pharmaceuticals, Inc.	5-lipoxygenase-activating protein (flap) inhibitors
US20070104620A1 (en)	2005-11-07	2007-05-10	Bilal Zuberi	Catalytic Exhaust Device
GB0522880D0 (en)	2005-11-09	2005-12-21	Glaxo Group Ltd	Novel compounds
WO2008030618A1 (en)	2006-09-07	2008-03-13	Amgen Inc.	Benzo-fused compounds for use in treating metabolic disorders
US20080255155A1 (en)	2006-10-18	2008-10-16	Stephane Raeppel	Kinase inhibitors and uses thereof
PT2848610T (pt)	2006-11-15	2017-11-14	Ym Biosciences Australia Pty	Inibidores da atividade de quinases
EP2125778A1 (en)	2006-12-22	2009-12-02	Millennium Pharmaceuticals, Inc.	Certain pyrazoline derivatives with kinase inhibitory activity
TW201006090A (en)	2008-07-16	2010-02-01	Chien-Chiang Chan	Applied structure of energy storage device
JP5754568B2 (ja)	2008-08-05	2015-07-29	ベーリンガーインゲルハイムインターナショナルゲゼルシャフトミットベシュレンクテルハフツング	４−ジメチルアミノ−フェニルで置換されているナフチリジン、及び医薬としてのその使用
WO2010015529A1 (en)	2008-08-05	2010-02-11	Nicox S.A.	New no releasing steroids derivatives
GB0910691D0 (en)	2009-06-19	2009-08-05	Glaxo Group Ltd	Novel compounds
US8912336B2 (en)	2009-11-06	2014-12-16	Vanderbilt University	Aryl and heteroaryl sulfones as mGluR4 allosteric potentiators, compositions, and methods of treating neurological dysfunction

2011
- 2011-03-11 GB GBGB1104153.0A patent/GB201104153D0/en not_active Ceased
2012
- 2012-03-08 ES ES15166109.7T patent/ES2641483T3/es active Active
- 2012-03-08 US US14/004,388 patent/US20140005177A1/en not_active Abandoned
- 2012-03-08 CN CN201280022632.7A patent/CN103502239B/zh not_active Expired - Fee Related
- 2012-03-08 KR KR1020137026876A patent/KR101564007B1/ko active IP Right Grant
- 2012-03-08 PL PL12707342T patent/PL2683709T3/pl unknown
- 2012-03-08 BR BR112013022784A patent/BR112013022784A2/pt not_active Application Discontinuation
- 2012-03-08 AR ARP120100750A patent/AR085711A1/es unknown
- 2012-03-08 WO PCT/EP2012/053948 patent/WO2012123311A1/en active Application Filing
- 2012-03-08 AU AU2012228439A patent/AU2012228439C1/en not_active Ceased
- 2012-03-08 RS RS20150449A patent/RS54120B1/en unknown
- 2012-03-08 HU HUE12707342A patent/HUE026541T2/en unknown
- 2012-03-08 UY UY0001033942A patent/UY33942A/es not_active Application Discontinuation
- 2012-03-08 ME MEP-2017-218A patent/ME02872B/me unknown
- 2012-03-08 LT LTEP15166109.7T patent/LT2937344T/lt unknown
- 2012-03-08 EP EP15166109.7A patent/EP2937344B1/en active Active
- 2012-03-08 PT PT151661097T patent/PT2937344T/pt unknown
- 2012-03-08 PE PE2013002037A patent/PE20140998A1/es active IP Right Grant
- 2012-03-08 DK DK12707342.7T patent/DK2683709T3/en active
- 2012-03-08 CA CA2828518A patent/CA2828518C/en not_active Expired - Fee Related
- 2012-03-08 EP EP12707342.7A patent/EP2683709B1/en active Active
- 2012-03-08 JP JP2013557086A patent/JP5902206B2/ja not_active Expired - Fee Related
- 2012-03-08 PL PL15166109T patent/PL2937344T3/pl unknown
- 2012-03-08 JO JOP/2012/0050A patent/JO3072B1/ar active
- 2012-03-08 EA EA201391165A patent/EA022437B1/ru not_active IP Right Cessation
- 2012-03-08 DK DK15166109.7T patent/DK2937344T3/en active
- 2012-03-08 HU HUE15166109A patent/HUE035443T2/en unknown
- 2012-03-08 TW TW101107813A patent/TWI527806B/zh not_active IP Right Cessation
- 2012-03-08 MA MA36313A patent/MA35030B1/fr unknown
- 2012-03-08 SG SG2013065750A patent/SG193015A1/en unknown
- 2012-03-08 PT PT127073427T patent/PT2683709E/pt unknown
- 2012-03-08 NO NO15166109A patent/NO2937344T3/no unknown
- 2012-03-08 SM SM20170538T patent/SMT201700538T1/it unknown
- 2012-03-08 RS RS20170962A patent/RS56719B1/sr unknown
- 2012-03-08 ES ES12707342.7T patent/ES2541530T3/es active Active
- 2012-03-08 ME MEP-2015-102A patent/ME02167B/me unknown
- 2012-03-08 SI SI201230253T patent/SI2683709T1/sl unknown
- 2012-03-08 MX MX2013010373A patent/MX339123B/es active IP Right Grant
- 2012-03-08 SI SI201231072T patent/SI2937344T1/sl unknown
- 2012-03-08 PH PH1/2013/501854A patent/PH12013501854A1/en unknown
- 2012-03-08 US US13/414,873 patent/US8993560B2/en not_active Expired - Fee Related
- 2012-03-08 MY MYPI2013701607A patent/MY169314A/en unknown
- 2012-08-03 UA UAA201310451A patent/UA109807C2/uk unknown
2013
- 2013-08-08 IL IL227873A patent/IL227873A/en active IP Right Grant
- 2013-08-20 CO CO13197322A patent/CO6791612A2/es active IP Right Grant
- 2013-08-30 ZA ZA2013/06554A patent/ZA201306554B/en unknown
- 2013-09-10 CL CL2013002602A patent/CL2013002602A1/es unknown
- 2013-09-11 DO DO2013000207A patent/DOP2013000207A/es unknown
- 2013-09-11 CR CR20130459A patent/CR20130459A/es unknown
2014
- 2014-06-24 HK HK14106105.3A patent/HK1192887A1/xx not_active IP Right Cessation
2015
- 2015-02-19 US US14/625,804 patent/US9447074B2/en not_active Expired - Fee Related
- 2015-07-08 HR HRP20150752TT patent/HRP20150752T1/hr unknown
- 2015-07-24 CY CY20151100654T patent/CY1116569T1/el unknown
- 2015-08-05 SM SM201500188T patent/SMT201500188B/xx unknown
2016
- 2016-04-27 HK HK16104812.0A patent/HK1216751A1/zh not_active IP Right Cessation
- 2016-08-19 US US15/241,160 patent/US20160355505A1/en not_active Abandoned
2017
- 2017-10-27 HR HRP20171647TT patent/HRP20171647T1/hr unknown
- 2017-11-08 CY CY20171101175T patent/CY1119581T1/el unknown

Also Published As

Publication number	Publication date
ES2641483T3 (es)	2017-11-10
RS56719B1 (sr)	2018-03-30
EA022437B1 (ru)	2015-12-30
JO3072B1 (ar)	2017-03-15
PL2683709T3 (pl)	2015-10-30
EP2683709B1 (en)	2015-05-06
HRP20171647T1 (hr)	2017-12-15
EP2937344B1 (en)	2017-08-23
US20150166508A1 (en)	2015-06-18
BR112013022784A2 (pt)	2016-12-06
CR20130459A (es)	2014-02-04
NZ614199A (en)	2015-10-30
CY1116569T1 (el)	2017-03-15
ZA201306554B (en)	2017-05-31
UY33942A (es)	2012-09-28
NO2937344T3 (es)	2018-01-20
PH12013501854A1 (en)	2022-04-08
US20120232061A1 (en)	2012-09-13
AR085711A1 (es)	2013-10-23
CL2013002602A1 (es)	2014-03-28
AU2012228439B2 (en)	2015-11-26
US9447074B2 (en)	2016-09-20
IL227873A (en)	2016-02-29
CN103502239B (zh)	2015-07-01
JP2014507457A (ja)	2014-03-27
CY1119581T1 (el)	2018-03-07
EP2683709A1 (en)	2014-01-15
JP5902206B2 (ja)	2016-04-13
RS54120B1 (en)	2015-12-31
KR101564007B1 (ko)	2015-10-28
KR20130143716A (ko)	2013-12-31
HUE035443T2 (en)	2018-05-02
DK2683709T3 (en)	2015-08-03
AU2012228439C1 (en)	2016-11-03
SI2937344T1 (sl)	2017-11-30
PE20140998A1 (es)	2014-09-04
CN103502239A (zh)	2014-01-08
SMT201500188B (it)	2015-09-07
MA35030B1 (fr)	2014-04-03
PT2937344T (pt)	2017-10-09
DOP2013000207A (es)	2014-04-30
EA201391165A1 (ru)	2014-03-31
DK2937344T3 (en)	2017-10-23
US20140005177A1 (en)	2014-01-02
CA2828518A1 (en)	2012-09-20
MY169314A (en)	2019-03-21
ME02167B (me)	2015-10-20
SMT201700538T1 (it)	2018-01-11
US20160355505A1 (en)	2016-12-08
ME02872B (me)	2018-04-20
AU2012228439A1 (en)	2013-05-02
EP2937344A1 (en)	2015-10-28
SI2683709T1 (sl)	2015-08-31
HUE026541T2 (en)	2016-06-28
HK1192887A1 (en)	2014-09-05
SG193015A1 (en)	2013-10-30
HK1216751A1 (zh)	2016-12-02
HRP20150752T1 (en)	2015-08-14
PL2937344T3 (pl)	2018-01-31
TWI527806B (zh)	2016-04-01
TW201249825A (en)	2012-12-16
LT2937344T (lt)	2017-11-10
CA2828518C (en)	2019-06-18
UA109807C2 (xx)	2015-10-12
WO2012123311A1 (en)	2012-09-20
PT2683709E (pt)	2015-09-15
MX339123B (es)	2016-05-12
MX2013010373A (es)	2013-10-30
US8993560B2 (en)	2015-03-31
IL227873A0 (en)	2013-09-30
ES2541530T3 (es)	2015-07-21
GB201104153D0 (en)	2011-04-27

Publication	Publication Date	Title
HRP20181429T1 (hr)	2018-11-30	Novi derivati benzimidazola kao inhibitori kinaze
CO6831983A2 (es)	2014-01-10	Compuestos heterocíclicos como inhibidores de cinasas
LT3181567T (lt)	2019-07-25	Pirazolpirimidino junginiai kaip kinazės slopikliai
BR112015003218A2 (pt)	2019-09-24	pirazolil-ureias como inibidores de cinase
IL238693A0 (en)	2015-06-30	Substituted tricyclic benzimidazoles as kinase inhibitors
BR112015002709A2 (pt)	2017-07-04	novos compostos de pirrolopirimidina como inibidores de proteínas quinases
CO6970602A2 (es)	2014-06-13	Inhibidores de quinasa
IL230561A0 (en)	2014-03-31	Inhibitors of bruton's tyrosine kinsae
EP2710007A4 (en)	2015-04-01	Kinase inhibitors
CO6880068A2 (es)	2014-02-28	Aminoquinazolinas como inhibidores de quinasa
CO6950479A2 (es)	2014-05-20	Compuestos de tetrahidroisoquinolina sustituidos como inhibidores del factor xia
DK2903618T3 (da)	2022-08-22	Rho-kinase-inhibitorer
DK3321262T3 (da)	2021-01-25	Serin-/threoninkinasehæmmere
EP2884982A4 (en)	2016-03-30	SUBSTITUTED PHENYL MILZ TYROSINE CHINASE INHIBITORS
EP2731612A4 (en)	2015-04-08	BRUTON TYROSINE KINASE HEMMER
BR112013029620A2 (pt)	2016-09-06	inibidores de tirosina quinase de bruton
HUE039897T2 (hu)	2019-02-28	Pirimidinil tirozin kináz inhibitorok
BR112013008527A2 (pt)	2016-07-12	derivados de pirazolo-quinazolina substituídos como inibidores de cinase
EP2917210A4 (en)	2016-05-25	KINASE INHIBITORS
CO6890101A2 (es)	2014-03-10	Inhibidores de pde10 de pirimidina
EP2916836A4 (en)	2016-08-03	AMINOPYRIDE-CONTAINING MILK TYROSINE KINASE (SYK) INHIBITOR
CO6791612A2 (es)	2013-11-14	Piridinilo- y pirazinilo-metiloxi - arilo derivados útiles como inhibidores de tirosina quinasa del bazo (syk)
CO6862145A2 (es)	2014-02-10	Imidazopiridazinas como inhibidores de quinasa akt
BR112015005361A2 (pt)	2017-07-04	inibidores de tirosina quinase de bruton
CO6990735A2 (es)	2014-07-10	Inhibidores de pirazina cinasa

Legal Events

Date	Code	Title	Description
2015-02-27	FG	Application granted